Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression
Conclusion:
All LAMAs were equally effective in preventing moderate-to-severe exacerbations. Aclidinium was associated with the lowest risk for severe exacerbations when treatment duration was 6 months or longer. The concomitant use of LABA may not enhance the efficacy of LAMAs in preventing COPD exacerbations. More studies are needed to further examine above findings.
Source: Therapeutic Advances in Respiratory Disease - Category: Respiratory Medicine Authors: Oba, Y., Lone, N. A. Tags: Original Research Source Type: research
More News: Aclidinium Bromide | Chronic Obstructive Pulmonary | Clinical Trials | Databases & Libraries | Respiratory Medicine | Spiriva | Statistics | Study | Tiotropium | Websites